Fibrosis is one of the leading causes of morbidity and mortality in the Western world. This disorder is characterised by an abnormal and increased rate of fibroblast proliferation and by an excessive deposition of connective tissue. The key player in fibrosis is the myofibroblast. Fibrosis leads to loss of organ structure and, eventually, to decrease in organ function. To date, there are hardly any effective therapies for the treatment of patients with fibrosis. Pirfenidone targets the myofibroblast and is effective in the treatment of idiopathic pulmonary fibrosis. Tyrosine kinase inhibitors are effective for the treatment of patients with some forms of systemic sclerosis. Here we describe various novel therapeutic targets, such as transforming growth factor beta (TGFβ), plateletderived growth factor (PDGF), interleukin13 (IL13), lysyloxidase2 and macrophagefibroblast interactions. These new therapies are currently under investigation in preclinical and clinical studies.
Nederlands Tijdschrift voor Geneeskunde
Erasmus MC: University Medical Center Rotterdam

Dalm, V., Dik, W., Thio, B., van den Blink, B., van Hagen, M., & van Daele, P. (2015). Fibrosing disorders: Insights into pathogenesis and new treatment options. Nederlands Tijdschrift voor Geneeskunde (Vol. 159). Retrieved from